coadministered cagrilintide and semaglutide in adults with overweight or obesity Cagrilintide–Semaglutide Type 2 Diabetes CagriSema Reduces Blood Pressure in
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2 Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity NEJM Ahmad Masri
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


